Teri Greiling is a Dermatology physician affiliated with Oregon Health & Science University. OpenAlex indexes 74 publications with 2,684 citations (h-index 18); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3303 SW Bond Ave # 16d
Ohsu Dermatology
Portland, OR 972394501
Telephone
503-494-4713Registry record last updated 22 Aug 2016.
Clinical trials
- Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
Sponsor: Oregon Health and Science University
- Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
Sponsor: Oregon Health and Science University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20251 payment
- GENZYME CORPORATIONProgram year20241 payment
- Janssen Scientific Affairs, LLCProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
22.2%Azole Antifungal8.2%Ketoconazole80%Fluconazole20%Part D<11 patientsSulfone4.4%Dapsone100%Part D≥15 patients+ 3 more classes in this area
Cancer & immunology
20.7%Folate Analog Metabolic Inhibitor7.8%Methotrexate82%Methotrexate Sodium18%Part D<11 patientsCalcineurin inhibitor5.7%Tacrolimus100%Part D≥23 patients+ 3 more classes in this area
Dermatology
18.8%Corticosteroid7.7%Triamcinolone Acetonide100%Part D≥36 patientsInterleukin-4 Receptor alpha Antagonist6%Dupixent Pen64%Dupixent Syringe36%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Orwoll, MD
Oregon Health & Science University
Aaron Caughey, MD
Oregon Health & Science University
Tomasz Beer, MD
Oregon Health & Science University
John Nutt, MD
Oregon Health & Science University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”